Overview
Ligandrol is a selective androgen receptor modulator (SARM) — a class of compounds that selectively bind to androgen receptors in muscle and bone tissue. Selective androgen receptor modulator.
With a half-life of ~1.2 days (30 hours), Ligandrol supports less frequent dosing schedules. Taken orally, it has a bioavailability of approximately 95% via its primary route.
Half-life approximately 30 hours. High oral bioavailability. One-compartment model. Not FDA-approved for human use.
Mechanism of Action
Ligandrol's pharmacological activity involves the following key pathways:
Selective Receptor Binding
Ligandrol is designed to selectively bind to androgen receptors in muscle and bone tissue, with reduced activity in other androgen-sensitive tissues.
Tissue Selectivity
The selectivity of Ligandrol is achieved through differential coactivator recruitment — the compound activates different downstream pathways depending on the tissue type.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
5 mg/day
Route
Oral
Frequency
Every other day
Duration
8-12 weeks
Dose
10 mg/day
Route
Oral
Frequency
Every other day
Duration
8-12 weeks
Frequently Asked Questions
What is LGD-4033 (Ligandrol) and how does it work?
LGD-4033 (Ligandrol) is a non-steroidal, orally active selective androgen receptor modulator (SARM) that binds to the androgen receptor with high affinity and selectivity. It preferentially stimulates anabolic activity in muscle and bone tissue while demonstrating reduced activity in the prostate. In clinical trials, dose-dependent increases in lean body mass were observed without significant changes in fat mass.
What is the half-life of LGD-4033?
LGD-4033 has an elimination half-life of approximately 24–36 hours, which supports convenient once-daily dosing. Pharmacokinetic studies show dose-proportional accumulation, with plasma levels approximately 3-fold higher at day 21 compared to day 1 of consistent administration. Steady-state concentrations are typically reached within 6–7 days.
How long does LGD-4033 take to show results?
Increased strength and improved training performance are commonly reported within the first 1–2 weeks. Visible changes in lean body mass and body composition are typically observed over 4–8 weeks of consistent dosing. Full effects on muscle development are generally reported at 8–12 weeks.
Does LGD-4033 suppress testosterone levels?
Clinical data demonstrates dose-dependent suppression of total testosterone, sex hormone-binding globulin (SHBG), and HDL cholesterol during LGD-4033 administration. Suppression effects are commonly observed even at lower doses. Hormone levels have been observed to return to baseline following treatment discontinuation, with recovery timelines of approximately 4–8 weeks reported.
What are the common side effects of LGD-4033?
Commonly reported effects include mild fatigue, dry mouth, light headaches, and nausea, which are typically transient. Testosterone suppression is the most consistently observed pharmacological effect, which may manifest as decreased libido and reduced energy during and shortly after a cycle. Mild water retention has been reported in some users during the first few weeks.
What is the typical LGD-4033 cycle length?
Cycle lengths of 8–12 weeks are most commonly reported in community protocols, with 8 weeks being standard for first-time users. Post-cycle therapy (PCT) is frequently observed following discontinuation due to the suppressive nature of the compound. A recovery period of at least 4 weeks between cycles is commonly recommended in community discussions.